ESMO Guidance for Reporting Oncology real-World evidence (GROW)

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Elm, E. V., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · BMJ · doi:10.1136/bmj.39335.541782.ad · Cited by 10,766

The Reporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) statement.

Benchimol, E. I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., Sørensen, H. T., von Elm, E., Langan, S. M., & RECORD Working Committee (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001885 · Cited by 5,749

To Explain or to Predict?

Galit Shmueli, A. (2010) · Statistical Science · doi:10.1214/10-sts330 · Cited by 3,392

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.

Hernán, M. A., & Robins, J. M. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv254 · Cited by 3,115

Statistics versus machine learning

Bzdok, D., Altman, N., & Krzywinski, M. (2018) · Nature Methods · doi:10.1038/nmeth.4642 · Cited by 1,508

Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials

Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445

Checklist for Artificial Intelligence in Medical Imaging (CLAIM): a guide for authors and reviewers

Mongan, J., Moy, L., & Kahn, C. E. (2020) · Radiology: Artificial Intelligence · doi:10.1148/ryai.2020200029 · Cited by 1,443

REporting recommendations for tumour MARKer prognostic studies (REMARK).

for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394

Identifying the PECO: A framework for formulating good questions to explore the association of environmental and other exposures with health outcomes

Morgan, R. L., Whaley, P., Thayer, K. A., & Schünemann, H. J. (2018) · Environment International · doi:10.1016/j.envint.2018.07.015 · Cited by 1,282

Risk of deficient mismatch repair colorectal cancer and precursors after kidney transplantation: A nationwide study

Zwart, K., van Kruijsdijk, R. C. M., Angerilli, V., Baas, M. C., Dekker, E., Rutgers, N., May, A. M., Koopman, M., Nagtegaal, I. D., & Bol, G. M. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.11.001 · Cited by 3

Real-world experience supporting the role of oncologic resection and adjuvant chemotherapy in biliary tract cancers

Boutin, M., Krishnan, T., Safro, M., Yang, J. C. C., Jafari, H., Davies, J. M., & Gill, S. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241247008 · Cited by 3

Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence

Schad, F., Thronicke, A., Hofheinz, R., Klein, R., Grabowski, P., Oei, S. L., Wüstefeld, H., & Grah, C. (2024) · Pharmaceuticals · doi:10.3390/ph17121713 · Cited by 3

Real-world treatment patterns and survival in patients with synchronous and metachronous metastatic colorectal cancer in the Netherlands

Elferink, M. A. G., van Erning, F. N., Sijtsma, F. P. C., Iersel, L. V., Wumkes, M. L., Roodhart, J. M. L., & Vink, G. R. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100153 · Cited by 6

Real-World Studies and Randomized Controlled Trials: A Podcast Discussion of the Relative Strengths and Limitations of These Complementary Designs for Cancer Research

Brufsky, A., Vaklavas, C., & Ryan, J. C. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00368-w · Cited by 3

Real-World Data of Patients with BRAF V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil

Ros, J., Ucha, J. M., García‐Galea, E., Gomez, P., Martini, G., Balconi, F., Comas, R., Alonso, V., Rodríguez-Castells, M., Baraibar, I., et al. (2024) · Cancers · doi:10.3390/cancers16244140 · Cited by 2

Real‐world treatment patterns and outcomes based on RAS / BRAF status in metastatic colorectal cancer—Analysis of the Prospective Dutch Colorectal Cancer cohort

van Nassau, S. C. M. W., Zwart, K., van der Baan, F. H., Vink, G. R., Elferink, M. A. G., Snæbjörnsson, P., May, A. M., Koopman, M., & Roodhart, J. M. L. (2025) · International Journal of Cancer · doi:10.1002/ijc.35410 · Cited by 2

Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma

Shim, S., Larsen, A. C., Bæksgaard, L., Pfeiffer, P., Nordsmark, M., Sørensen, J. R., Motavaf, A. K., & Ladekarl, M. B. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100183 · Cited by 2

Real-World Toxicity and Effectiveness Study of Abemaciclib in Greek Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Multi-Institutional Study

Fountzilas, E., Aravantinou-Fatorou, E., Dadouli, K., Economopoulou, P., Tryfonopoulos, D. J., Vernadou, A., Vorrias, E., Vagionas, A., Nikolaidi, A., Karageorgopoulou, S., et al. (2025) · Cancers · doi:10.3390/cancers17152543 · Cited by 3

Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients

Farolfi, A., Casadei, C., Gentili, N., Testoni, S., Rusconi, F., Giunta, E. F., Brighi, N., Gurioli, G., Montanari, D., Hernández, G., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf243 · Cited by 2

Finding the right tool for the specific task: navigating RWE tools and checklists

Willke, R. J., Cottu, P. H., Briggs, A. H., Siebert, U., Chen, C., Korytowsky, B., Heidt, J., Renfrow, M., Lovett, K., & Brufsky, A. (2025) · Future Oncology · doi:10.1080/14796694.2025.2552098 · Cited by 2

High Adherence to Adjuvant Endocrine Therapy Improves Outcome in Early Breast Cancer – Results from a Large Real-World Claims Data Analysis in Germany

Engler, T., Hartkopf, A. D., Dannehl, D., Dijkstra, T. M. H., Volmer, L. L., Hahn, M., von Au, A., Hawighorst‐Knapstein, S., Chaudhuri, A., Wallwiener, M., et al. (2025) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2687-9258 · Cited by 2

Enhancing confidence in complex health technology assessments by using real-world evidence: highlighting existing strategies for effective drug evaluation

Antoine, A., Desroziers, K., Dupin, J., Pérol, D., & Choquet, R. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02683-2 · Cited by 2

One- and two-year overall survival following stereotactic body radiotherapy versus conventional radiotherapy for pancreatic cancer: a systematic review and meta-analysis

Yang, M., Huo, Y., Kuang, D., Zhao, Y., Tan, S., Huang, Y., Fan, S., & Zhang, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003992 · Cited by 2

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours

Saini, K., Koopman, M., Martins-Branco, D. A., Bossi, P., Winther, S. B., Brahmi, M., Braña, I., Calvo, E., Castelo-Branco, L., Colombo, I., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.02.008 · Cited by 2

Ability of computed tomography and endoscopic ultrasound to predict pathological tumor node metastasis staging of resected ampullary carcinomas (ACs): an analysis of the Fédération Française de Cancérologie Digestive AC prospective cohort study

Pellat, A., Manfrédi, S., Truant, S., Roth, G. S., Malicot, K. L., Bouché, O., Piessen, G., Tougeron, D., Coriat, R., Jary, M., et al. (2026) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2026.02.012 · Cited by 2

Machine Learning Predicts Hepatocellular Carcinoma Risk from Routine Clinical Data: A Large Population-Based Multicentric Study

Clusmann, J., Koop, P., Zhang, D. Y., van Haag, F., Nahhas, O. S. M. E., Seibel, T., Žigutytė, L., Kaewdech, A., Caldéraro, J., Tacke, F., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1323 · Cited by 6

Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?

Bermejo, B., Dienstmann, R., Bellet, M., de la Cruz, S., Galve-Calvo, E., Obadía, V., Santaballa, A., Ramos‐Medina, R., Cuenca, M., & Moreno, F. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0186 · Cited by 2

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation

Liu, J., Beal, J. R., Coleman, N., Ma, B. B. Y., Loong, H. H.-F., Zhao, H., Seymour, L., Westphalen, C. B., Curigliano, G., & Subbiah, V. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00034 · Cited by 3

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC

Andersen, R., Jespersen, M. S., Presti, M., Bjørnhart, B., Østby, A.-C. B., Darras, A. K. M., Garitaonaindía, Y., Ruhlmann, C. H. B., Frank, M. S., Schmidt, H., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116872 · Cited by 2

Social inequalities in return-to-work among colorectal cancer survivors in Germany

Soff, J., Demirer, I., Sibert, N. T., Breidenbach, C., Ernstmann, N., Heidkamp, P., Heier, L., Hiltrop, K., Schellack, S. K., Weiß, J., et al. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10827-3 · Cited by 2

Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study

Brandell, J. K., Valachis, A., Ugge, H., Smith, D. R., & Johansson, B. H. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100846 · Cited by 2

Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours

Pellat, A., Grinda, T., Morgado, P. C., Prelaj, A., Miskovic, V., Valachis, A., Zerdes, I., Martins-Branco, D. A., Provenzano, L., Spagnoletti, A., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100091 · Cited by 3

Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting

Olsson, E. M. G., Lindman, H., Digkas, E., Thurfjell, V., Ali, H. M., Krüger, U., Wennstig, A.-K., Sundqvist, M., & Valachis, A. (2025) · The Breast · doi:10.1016/j.breast.2025.103874 · Cited by 2

Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records

Mazzeo, L., Corso, F., Baili, P., Scotti, F., Torri, V., Ganzinelli, M., Miskovic, V., Leporati, R., Provenzano, L., Spagnoletti, A., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100109 · Cited by 3

Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients

Verschueren, M. V., Hiensch, D. T. A., Plomp, P. M. J., Kastelijn, L. E. A., van de Garde, E. M. W., & Peters, B. J. M. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.01.009 · Cited by 2

Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry

Macarulla, T. M., Martín, A. J. M., de Castro, E. M., Trujillo, O. A. C., Cano, M. T., Castet, F., Tocino, R. V., Arias, A. F., Ghanem, I., Díaz, I. A., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100116 · Cited by 2

Core variables for real-world clinicogenomic data collection in precision oncology

Dienstmann, R., Hackshaw, A. K., Blay, J., & Tourneau, C. L. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100117 · Cited by 2

Precision Oncology Program (POP), an observational study using real-world data and imaging mass cytometry to explore decision support for the Molecular Tumor Board: study protocol

Boos, L. A., Dörig, C., Gut, G., Miglino, N., Ibáñez, L. F., Rizzo, S., Fruechtenicht, C., Chitale, N., Lu, C., Zoche, M., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-096591 · Cited by 2

Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW)

Thronicke, A., Grabowski, P., Roos, J. A. D. M. D., Wüstefeld, H., Grah, C., Johnson, S., & Schad, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083669 · Cited by 2

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study

Lobo-Martins, S., Debien, V., Agostinetto, E., Sirico, M., Carvalho, G. D. S., Jacobs, F., Molinelli, C., Bonadio, R. C., Bergmann, P., Souza, C. D. P., et al. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.05.002 · Cited by 2

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Ishihara, M., Kawamura, T., Namba, Y., Takeyasu, Y., Hasegawa, Y., Sato, Y., Negi, Y., Oba, T., Sumi, T., Hirata, H., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251344010 · Cited by 2

Accuracy of PET–CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment

Stoff, R., Yalon, M., Thorpe, M. P., Flotte, T. J., Block, M. S., & Hieken, T. J. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18191-y · Cited by 2

Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study

Liu, X., Binicy, B. K., Ács, B., Eriksson, L., Loibl, S., Gnant, M., Untch, M., Valachis, A., Bergh, J. C. S., Hartman, J., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101471 · Cited by 2

Association between low-dose aspirin and the risk of gastric cancer and adenoma according to a family history of gastric cancer

Jung, Y. S., Trần, T. X. M., Park, B., & Moon, C. M. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.02.013 · Cited by 2

EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain

Fernández, R., Sagastibeltza, N., Obis, E. P., Milagro, N. L., Sánchez-Escribano, R., Kareaga, M. M., Aguilar, J. A. V., Ibarbia, M. A., González, M. P., del Rivero, T. D. P. F., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100063 · Cited by 1

Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort

Giugliano, F., Bertaut, A., Blanc, J., Martin, A., Gaudin, C., Fournier, M., Kieffer, A., Sauterey, B., Levy, C., Campone, M., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103994 · Cited by 1

The association between level IV/V metastasis and the recurrence, distant metastasis, and survival outcomes in hypopharyngeal squamous cell carcinoma

Li, R., Wang, Q., Ma, S., Li, J., Zhao, Y., & Wang, X. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241312079 · Cited by 1

The MELimmune score—prognostic factors for overall survival in advanced melanoma and anti-PD-1 monotherapy—a multicentre, retrospective cohort study

Lobo-Martins, S., Martins-Branco, D. A., Semedo, P. M., Alvim, C. M., Monteiro, A. M., Vendrell, I., Gouveia, E. J., Passos, M. J., Costa, L., Mansinho, A., et al. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101043 · Cited by 1

Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review

Verschueren, M. V., Tassopoulou, V. P., Visscher, R., Schuurkamp, J., Peters, B. J. M., Koopman, M., van de Garde, E. M. W., Egberts, T. C. G., & Bloem, L. T. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100118 · Cited by 1

Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study

Heudel, P., Hernandez, G., Denquin, O., Crochet, H., & Blay, J. (2025) · JMIR Cancer · doi:10.2196/64900 · Cited by 1

Impact of HRR Gene Subclass on Clinical Outcomes of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer

Dimitrov, G., & Popov, E. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102411 · Cited by 1

Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland

Drobniak, A., Stokłosa, Ł., Grela-Wojewoda, A., Calik, J., Viegas, N. V., Dobrzańska, J., Roman, A., Szwiec, M., Bidas, A., Tusień-Małecka, D., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1617743 · Cited by 1

Analysis of the Current Status and Characteristics of Health Economics Reporting in Clinical Practice Guidelines for 2021–2023

Xing, X., Zhang, G., Kong, W., Guo, L., Li, X., Wei, Z., Lu, Y., White, H., Chen, Y., & Yang, K. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70062 · Cited by 1

S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure

Tang, H. J., Li, Z., You, T., Ying, J., Yuan, M., Cheng, Y., Wang, Y., Wu, H., & Bai, C. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251378698 · Cited by 1

Outcomes in relapsed/refractory diffuse large B-cell lymphoma in an Asian tertiary cancer center: real-world interventions as benchmark for novel therapy

Lim, N.-A., Sun, Y., Tan, J. Y., Lim, R. M. H., Tan, Y. H., Ng, L. C. K., Lim, F., Goh, Y. T., Hoe, J. T. M., Chiang, J., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100195 · Cited by 1

Characteristics, treatment, and outcome of recurrent gastro-oesophageal adenocarcinoma after perioperative chemotherapy and radical resection

Larsen, A. C., Shim, S., Bæksgaard, L., Pfeiffer, P., Nordsmark, M., Sørensen, J. R., Brøndum, R. F., Krejbjerg, A., & Ladekarl, M. B. (2026) · Acta Oncologica · doi:10.2340/1651-226x.2026.44264 · Cited by 1

Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real‐World Data

Pignatti, F., El‐Galaly, T. C., Kaiser, M., Porkka, K., Doeswijk, R., Mol, P. G. M., Rivera, D. R. R., Lerro, C. C., Rohr, U., Verpillat, P., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70213 · Cited by 1

Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study

Ghedri, A., van der Baan, F. H., Otten, J., Elferink, M. A. G., Terheggen, F., Hendriks, M. P., May, A. M., Koopman, M., Punt, C. J. A., & Kwakman, J. J. M. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116588 · Cited by 1

Diagnostic Documentation and Tumour Marker Availability Across Clinical Pathways in Real-World Gastric Cancer

Vieru, A.-M., Rădulescu, V. M., Mustață, M.-L., Traşcă, E. T., Cazacu, S. M., Popa, P., & Ciurea, T. (2026) · Diagnostics · doi:10.3390/diagnostics16071002 · Cited by 1

Impact of COVID-19 and vaccination on long-term survival in patients with solid malignancies: A nationwide cohort study

Dimitrov, G., Argirova, R., & Valkov, T. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116708 · Cited by 1

Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer

Marta, G. N., Zheng, Y., Rosenberg, S. M., Dibble, K. E., Mayer, E. L., Poorvu, P. D., Ruddy, K. J., Guzmán‐Arocho, Y. D., Collins, L. C., Peppercorn, J. M., et al. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag152 · Cited by 1

Clinical and pathologic insights into early and late breast cancer relapses: a real-world analysis from the El Álamo IV registry

Fraile-Lara, L., Andrés, R., Servitja, S., Carrasco, E., Guerrero, Á., Bermejo, B., Antón, A., Cruz, J., Álvarez, I., Aguiar, D., et al. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04419-0 · Cited by 1

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study

Martins-Branco, D. A., Lobo-Martins, S., Aftimos, P. G., Pereira, B. A., de Matos, L. V., Fernandes, L., Campôa, E., Marta, G. N., Moreau, M., Taylor, D., et al. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-08012-5 · Cited by 1

Inconsistent reporting of adolescent and young adult (AYA) status in non-interventional cancer research: a critical barrier to evidence usability

Reuter, K., Freyer, D. R., Milam, J. E., & Mobley, E. M. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-107742 · Cited by 1

Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study

Carola, É., Caillet, P., Falandry, C., Tassy, L., lawrence, I., Paillaud, É., Pulido, M., de Lempdes, G. R., Bringuier, M., Jovenin, N., et al. (2026) · The Breast · doi:10.1016/j.breast.2026.104879 · Cited by 1

Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases

Hao, Y., Xu, M., Zeng, X., Wang, Y., Wang, W., Lin, G., Li, B., Huang, J., Xu, C., Zhang, Y., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241253127 · Cited by 1

Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)

Courtinard, C., Barbet, V., Schiappa, R., Pilleul, F., Michiels, S., Dabakuyo‐Yonli, T. S., Gourgou, S., Jaffré, A., Asselain, B. J. R., Bosquet, L., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100043 · Cited by 1

A comparison between single and fractionated doses of albumin-bound paclitaxel in the treatment of advanced esophageal cancer: A multicenter case–control study

Ren, J., Wang, K., Zhao, J., Xu, C., Liu, C., Wang, Y., & Wang, G. (2024) · Science Progress · doi:10.1177/00368504241299016 · Cited by 1

Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study

Hosseini-Mellner, S., Wickberg, Å., Olsson, E. M. G., Karakatsanis, A., & Valachis, A. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100093 · Cited by 1

A multicenter retrospective study of the combination of immune checkpoint inhibitors and chemotherapy regimens with or without liver metastasis for the first-line treatment of advanced gastric cancer

Ren, J., Wang, K., Meng, Q., Xu, C., Liu, C., Wang, Y., & Wang, G. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308389 · Cited by 1

Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer

Olsén, J. S., Valachis, A., & Johansson, B. H. (2025) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2025.100923 · Cited by 1

Interim results analysis of the PERFECTION observational study in patients with metastatic non-small cell lung cancer

Лактионов, К. К., Fedyanin, M. Y., Stroyakovskiy, D., Mochalova, A. S., Iasieva, A. R., Fadeeva, N., Шаповалова, Ю. С., Mironov, O. V., Сергеевич, Д. А., Orlov, S., et al. (2025) · Journal of Modern Oncology · doi:10.26442/18151434.2024.4.203109 · Cited by 1

What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?

Dalbeni, A., Cattazzo, F., Natola, L. A., Zoncapè, M., Faccincani, D., Stefanini, B., Ravaioli, F., Villani, R., Auriemma, A., & Sacerdoti, D. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2476541 · Cited by 1

PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network

Rippstein, N., Zemmour, C., Rodrigues, M. J., Ray-Coquard, I. L., Gladieff, L., Pautier, P., Frenel, J., Costaz, H., Lebreton, C., Pomel, C., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf075 · Cited by 1

Real-world efficacy and safety of nivolumab and ipilimumab in metastatic renal cell carcinoma: a Polish multicenter study

Pacholczak‐Madej, R., Drobniak, A., Stokłosa, Ł., Grela-Wojewoda, A., Calik, J., Viegas, N. V., Tusień-Małecka, D., Szwiec, M., Dobrzańska, J., Roman, A., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2508138 · Cited by 1

Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis

van Marcke, C., Pogoda, K., Fenton, H. M., Vallet, M., Plavc, G., Borges, M., Yousuf, H., Dumas, É., Berlière, M., Ciliberto, G., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100158 · Cited by 2

Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy: a new irAE from real-life data

Baddi, S., Suarez, D., Ruet, A., Butsel, T. V., Cerasuolo, D., Rat, A., & L'Orphelin, J. ‐. (2025) · Scientific Reports · doi:10.1038/s41598-025-08974-4 · Cited by 1

ESMO Real-World Data and Digital Oncology: a journal to understand how health systems can help provide better cancer care

Dienstmann, R. (2023) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2023.09.002

Real-World Evidence from the TriNetX Network: Assessing Immunotherapy's Impact on Second Primary Cancer Risk in Metastatic Lung Cancer (Preprint)Preprint

Heudel, P., Hernandez, G., Denquin, O., Crochet, H., & Blay, J. (2024) · doi:10.2196/preprints.64900

Patterns and outcomes in HR+/HER2- advanced/metastatic breast cancer patients in Brazil receiving palbociclib

Simon, P., Jain, A., Guarin, A., Piton, L., Carvalho, C. F., Lima, J., & Nazareth, F. (2024) · Future Oncology · doi:10.1080/14796694.2024.2388022

Real-world efficacy of PD-1/PD-L1 inhibitors in patients with advanced pulmonary neuroendocrine carcinoma: a single-center analysis

Zhai, W., Yu, Y., Wu, H., Zhang, Q., Chen, Y., Yang, Y., & Fan, Y. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241288130

Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data

Lee, D., Meléndez‐Torres, G. J., Challapalli, A., Frazer, R. D., McGrane, J., & Bahl, A. K. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100087

Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study

Salfi, G., Pedrani, M., Candan, S., Urechie, V., Merler, S., Ruinelli, L., Colombo, A., Castelo-Branco, L., Testi, I., Turco, F., et al. (2024) · European Urology Open Science · doi:10.1016/j.euros.2024.10.023

Primary hyperparathyroidism in patients with thyroid cancer: prevalence and prognosis in a retrospective monocentric study

Patelli, I., Comina, M., Musso, L., di Pietralata, A. D., Vera, L., Minuto, M. N., Albertelli, M., Giusti, M., Bagnasco, M., Ferone, D., et al. (2024) · Endocrine · doi:10.1007/s12020-024-04142-2

Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d’Oncologia Breast Cancer Observational Cohort Study

Pla, H., Fullana, B., Esteve, A., Fort‐Culillas, R., Ferrando‐Díez, A., Fernández-Ortega, A., Pous, A., Stradella, A., Villanueva-Vázquez, R., Cirauqui, B., et al. (2025) · Cancers · doi:10.3390/cancers17081366

Prevalence of functional iron deficiency in patients with malignancies and its impact on fatigue-specific quality of life

Zimmermann, S., Aebi, S. P., Gautschi, O. P., Gregor, M., Müller, B. P., Nilius, H., Pardo, E., Weiler, D., Zeerleder, S. S., & Rüfer, A. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100140

A Prospective Study on the Financial Impact of Breast Cancer Treatment over a One-Year Period for Patients at a Rural Cancer CenterPreprint

Manko, C. D., Khan, K., Zlupko, T. J., Witteveen, N., Thresher, E., Panek, J., Inamdar, A., & Perry-Keaty, C. (2025) · medRxiv · doi:10.1101/2025.05.07.25326315

Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer

Murray, J. C., Huang, Q., Chen, Y.-C., Hu, C., DiSantostefano, R. L., Wong, C. K. H., Glatz, L., Curran, E., Villaruz, L. C., Hasan, A. N., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100148

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019

Moscetti, L. I., Barbieri, E., Zattarin, E., Vici, P., Zoppoli, G. M., Musolino, A., Natalizio, S., Canino, F., Ravera, F., Filomeno, L., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100154 · Cited by 1

Challenges in analyzing real-world evidence: analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study

Tran, B., Yeh, N., Gayle, A., Holmes, E., Hu, J., Damineni, S., Kebede, N., & Shore, N. D. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100149

Combination regimens as potential treatment of non-small-cell lung cancer patients with HER2 mutation in the real world: a multicenter study

Hao, Y., Wang, Q., Wang, K., Chen, C., Xu, C., Wang, D., Song, Y. P., Song, Z., & Lv, T. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251338397

Palbociclib: randomisierte Studien und Real-World-Evidenz als Grundlage für die Therapieplanung beim metastasierten Mammakarzinom

Ruckhäberle, E., Schmidt, M., Welt, A., Harbeck, N., Wöckel, A., Gluz, O., Park‐Simon, T., Untch, M., & Lux, M. P. (2025) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2579-9530

A Standardized Guideline for Assessing Extracted Electronic Health Records Cohorts: A Scoping Review.

Songthangtham, N., Jantraporn, R., Weinfurter, E., Simon, G., Pan, W., Rajamani, S., & Johnson, S. (2025) · Europe PMC (PubMed Central)

Systematic curation and analysis of ovarian cancer data across multiple electronic record systems held within the UK National Health Service: a tertiary referral centre experience

Samani, A., Giannone, G., Mercuri, L., Jiang, R., Nadkarni, Y., Chadha, A., Xing, E., Ghaem‐Maghami, S., Krell, J. M., Lyons, D., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100150

Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort Study

Dauccia, C., Martins-Branco, D. A., Moreau, M., Ameye, L., Agostinetto, E., Arecco, L., Lobo-Martins, S., Skoporc, A., Vilas-Boas, I., Auprih, M., et al. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.06.011

Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort Study

Tsai, I.-L., Lin, C., Su, P., Lin, C., Chang, J. W., Huang, C., Fang, Y., Chang, C., Kuo, C. S., Hsu, P., et al. (2025) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251348367

KI in der medizinischen Forschung

Kather, J. N. (2025) · Springer eBooks · doi:10.1007/978-3-662-71042-5_6

Prognostic factors for metastatic gastrointestinal stromal tumors treated with cytoreductive surgery: a retrospective cohort study

Zhang, H., Yin, X., Mu, M., Chen, H., Cai, Z., Shen, C., Yin, Y., & Zhang, B. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2544312

Heterogeneity of treatment preferences in the absence of guideline recommendations – a case vignette study in colorectal cancer tumor boards in Germany, Austria and Switzerland

Soff, J., Benz, S. R., Kowalski, C., Hansinger, J., Gerken, M., Maier, D., Kim-Wanner, S.-Z., Witzmann, J., Reinacher‐Schick, A., Pox, C. P., et al. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04183-5

Prognostic role of Ki-67 in high-risk estrogen receptor-positive/HER2-negative early breast cancer: a population-based cohort study

Tegnelius, E., Ahlgren, J., & Valachis, A. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100647

The reporting of health systems data use in primary results publications of clinical trials: a systematic review

Thompson, J., Bobou, M., Roberts, K., Taheri, S., Love, S., & Murray, M. L. (2025) · Trials · doi:10.1186/s13063-025-09227-5

Long-Term Survival in a Large Spanish Breast Cancer Cohort: Age-Stratified Outcomes from the Institut Català d’Oncologia (2010-2014) Observational Study

Morgan, A. L., Foster, D. K., & Collins, I. J. (2025) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/trgmgegzkr

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2− advanced breast cancer treated with CDK4/6 inhibitors

Torrisi, R., Giugliano, F., Giordano, L., Saltalamacchia, G., Jacobs, F., Schianca, A. C., Milano, M., Bianco, N., Sangalli, C. A., De Sanctis, R., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag003

Evolution of the sentinel lymph node procedure following the approval of adjuvant anti-PD-1 therapy for stage IIB and IIC melanoma: A multicenter study from RICMEL database

Deriouich, M., Levard, R., Tagmouti, T., Sanogo, D., Cassecuel, J., Khammari, A., Quereux, G., Dompmartin, A., Dréno, B., & L'Orphelin, J.-M. (2026) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2025.103463

Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care

Sellmann, L., Marschner, D., Martens, U. M., Schröder, J., Decker, T., Schuler, M. K., Schneeweiss, A., Reiser, M., Schuler, M. K., Vannier, C., et al. (2026) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100667

Real-world demographics, clinical characteristics, and testing and treatment patterns in patients with non-small-cell lung cancer and extensive-stage small-cell lung cancer in Belgium: the AIBED study

Muylle, K., Decoster, L., Verleyen, D., Germonpre, P. R., Masuy, I., Verheyden, B., Oeste, C. L., Callewaert, E., Derijcke, S., Wauters, E., et al. (2026) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100668

Renal Cell Carcinoma: Characteristics of Patients, Treatment, and Disease Progression Based on Real-World Data From a Cancer Center in Medellín, Colombia

Lema, M., Lema, C., Morán, D., Pineda, M., Preciado, B., & Pérez, E. (2026) · Cureus · doi:10.7759/cureus.102306

Clinicopathological Features, Treatment Patterns, and Outcomes of High-Risk Early Hormone Receptor–Positive Breast Cancer in a French Real-World Cohort

Clark, R. J., & Smith, A. (2023) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/14quxt7qqr

Real-World Evidence in Oncology: Opportunities and Limitations

Maïo, M. D., Perrone, F., & Conte, P. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0647 · Cited by 181

Pré-test

Pellat, A., & Grinda, T. (2024) · Hépato-Gastro & Oncologie Digestive · doi:10.1684/hpg.2024.2812

Real-world evidence studies in oncology: a trend or a necessity?

Zhuravkov, A., Moiseenko, F. V., Колбин, А. С., & Moiseyenko, V. M. (2023) · Practical oncology · doi:10.31917/2401059 · Cited by 3

Longitudinal trends of real-world evidence (RWE) reporting in oncology conferences: An 11-year ASCO Annual Meeting analysis.

Azad, F., Zhang, J., Akhtar, O. S., George, A. M., Attwood, K. M., & Torka, P. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.e18748 · Cited by 1

Editorial: Real-world data and real-world evidence in lung cancer

Gristina, V., & Eze, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1436077 · Cited by 9